Tween 20 Excipient | Pharma Excipients | News | Suppliers

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Virtual Booth

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

INACTIVE PHARMA INGREDIENTS

3 Suppliers, 2 USDMF, 1 CEP/COS, 5 Listed Suppliers

3 Suppliers
2 USDMF
1 CEP/COS
5 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

63 FDF Dossiers Suppliers, 41 FDA Listed Dossiers

63 FDF Dossiers Suppliers
41 FDA Listed Dossiers

EXCIPIENTS BY APPLICATIONS

4 Solubilizers, 3 Surfactant & Foaming Agents, 3 Parenteral, 2 Topical, 2 Emulsifying Agents, 1 Thickeners and Stabilizers

4 Solubilizers
3 Surfactant & Foaming Agents
3 Parenteral
2 Topical
2 Emulsifying Agents
1 Thickeners and Stabilizers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 1 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
1 NEWS #PharmaBuzz

MARKET PLACE

3 EXCIPIENTS

3 EXCIPIENTS

REF. STANDARDS & IMPURITIES

1 Others

1 Others

SUPPLIERS

01

Nanjing Well Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #12.1G60

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF

Click Us!

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Hubei Gedian Humanwell Pharmaceuti...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ESCRS

Not Confirmed

03

Kolb Distribution Ltd

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

ESCRS

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Nanjing Well Pharmaceutical Group Co...

China

CPhI WW Frankfurt

Booth #12.1G60

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Contact Supplier

China

Virtual Booth

Digital Content

EXCIPIENT POLYSORBATE 20

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36565

Submission : 2022-07-05

Status : Active

Type : IV

02

Hubei Gedian Humanwell Pharmaceutica...

China

SCI Medicinal Chemistry

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

01

KOLB DISTRIBUTION LTD. Hedingen CH

Switzerland

SCI Medicinal Chemistry

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FINISHED DOSAGE FORMULATIONS

Upload your portfolio for free, ask us

FDF DOSSIERS SUPPLIERS

01

SANOFI AVENTIS US

France

CPhI WW Frankfurt

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

INSULIN GLARGINE RECOMBINANT

Drug : LANTUS SOLOSTAR

Dosage Form : INJECTABLE; INJECTION

Application Number : 21081

Country : US

Patented : No

Portfolio PDF

Product Web Link

02

SANOFI AVENTIS US

France

CPhI WW Frankfurt

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

INSULIN GLARGINE RECOMBINANT

Drug : LANTUS

Dosage Form : INJECTABLE; INJECTION

Application Number : 21081

Country : US

Patented : No

Portfolio PDF

Product Web Link

03

ABBVIE

U.S.A

NASP

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

CALCITRIOL

Drug : CALCIJEX

Dosage Form : INJECTABLE; INJECTION

Application Number : 18874

Country : US

Patented : No

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

STRIDES PHARMA

India

CPhI WW Frankfurt

Booth # 9.1F6 & 9.1G41

Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

Drug : AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

Dosage Form : TABLET; ORAL

Application Number : 201087

Country : US

Patented : No

Portfolio PDF

Product Web Link

JANSSEN BIOTECH

DARATUMUMAB

NASP

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Listed Dossiers

01

Dosage Form : SUSPENSION, LIQUID

POLYSORBATE 20

CPhI Korea

Not Confirmed

Not Confirmed

Only 10 entries up to this point, click to access all

EXCIPIENTS BY APPLICATIONS

Click here to find the perfect excipient manufacturers by their capabilities

Solubilizers

Surfactant Foaming Agents

Parenteral

Topical

Emulsifying Agents

Thickeners And Stabilizers

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards. Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio. Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients. The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.